BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Revolution Medicines (RVMD) presented full Phase 3 RASolute 302 data at the ASCO plenary on Saturday. The detailed results confirmed and expanded the topline: median PFS 7.2 months vs. 3.6 months (HR 0.49, p<0.0001) and median OS 13.2 months vs. 6.7 months (HR 0.40, p<0.0001) in the ITT population (500 patients). Results were consistent across the RAS G12 population. The data were published simultaneously in The New England Journal of Medicine. The FDA granted expanded access to daraxonrasib. Revolution intends to file an NDA under the CNPV program.
Akeso's ivonescimab (PD-1/VEGF bispecific) plus chemotherapy demonstrated a statistically significant overall survival benefit over PD-1 plus chemotherapy in first-line squamous NSCLC (HARMONi-6, OS HR 0.66). This is the first China-originated drug selected for the ASCO plenary session in the society's 61-year history. Summit Therapeutics is the U.S. partner.
Johnson & Johnson's (JNJ) Phase 3 PROTEUS study showed Erleada (apalutamide) before and after surgery significantly reduced the risk of metastasis or death versus hormone therapy alone in high-risk localized or locally advanced prostate cancer. J&J's oncology leadership called it "one chance for curing this patient." The study opened the plenary.
Your ASCO field guide is live. Searchable, filterable, catalyst-aware. Bookmark it → biomednexus.com/asco-2026
⚡ Executive Takeaway
Saturday's ASCO plenary delivered three datasets that will change how cancer is treated. Revolution's full RASolute 302 data confirmed everything the topline promised and added the missing piece: PFS. At 7.2 months versus 3.6 months (HR 0.49), daraxonrasib doubled progression-free survival in second-line pancreatic cancer, matching the OS doubling (13.2 vs. 6.7 months) we reported in April. The results held across both the RAS G12 population and the ITT population (which includes patients without identified RAS mutations), meaning the drug works broadly. The simultaneous NEJM publication is the strongest possible scientific endorsement. The FDA's expanded access decision means patients can start receiving daraxonrasib before formal approval. Revolution plans to file under CNPV. Truist projected Q3 approval. Meanwhile, Akeso's ivonescimab made history as the first Chinese drug in the ASCO plenary. The OS HR of 0.66 against PD-1 plus chemo in squamous NSCLC is a genuine practice-changing result. If confirmed in global studies, ivonescimab (partnered with Summit Therapeutics in the U.S.) could challenge Keytruda's dominance in lung cancer. And J&J's PROTEUS data showed that adding Erleada before and after prostate surgery reduced metastasis or death in a 2,000-patient study, addressing what J&J called a "125-year treatment gap." 👉 Read Full Analysis
🔮 What To Watch
Revolution Medicines CNPV Filing: Filing expected imminently. If CNPV review mirrors the 50-day Foundayo precedent, approval could come by August or September 2026.
Daraxonrasib Expanded Access: Patients with previously treated metastatic PDAC can now access daraxonrasib before formal approval. Watch for uptake data.
Ivonescimab U.S. Strategy: Summit Therapeutics holds U.S. rights. An FDA filing based on Chinese data would face regulatory scrutiny. A U.S. confirmatory trial may be required. The path from ASCO plenary to U.S. approval is not guaranteed.
Erleada PROTEUS Label Expansion: J&J will seek FDA approval for the perioperative prostate cancer indication. If approved, Erleada expands from advanced/metastatic disease into the curative setting.
ASCO Continues Through Tomorrow: Additional data presentations today and tomorrow. Conference closes June 2.
🚀 Top Story
Revolution Medicines Confirms Practice-Changing Data in Pancreatic Cancer, Publishes in NEJM RVMD
What Happened: Brian Wolpin, MD, MPH (Dana-Farber Cancer Institute) presented the primary and final analysis of the Phase 3 RASolute 302 trial in a plenary session (LBA5) at ASCO on Saturday May 31 at 3:21 PM CDT. The data were published simultaneously in The New England Journal of Medicine.
The Full Data (500 patients, data cutoff February 10, 2026, median follow-up 8.5 months):
Intent-to-Treat Population (daraxonrasib n=248, chemotherapy n=252):
Median OS: 13.2 months vs. 6.7 months. HR 0.40 (95% CI: 0.30 to 0.53; p<0.0001). 60% reduction in risk of death.
Median PFS: 7.2 months vs. 3.6 months. HR 0.49 (95% CI: 0.38 to 0.64; p<0.0001). 51% reduction in risk of progression or death.
RAS G12 Population (daraxonrasib n=228, chemotherapy n=231):
OS: HR 0.40 (60% reduction in risk of death). Consistent with ITT.
Median PFS: 7.3 months vs. 3.5 months. HR 0.45 (95% CI: 0.34 to 0.59; p<0.0001). 55% reduction in risk of progression or death.
Safety was generally well tolerated with a manageable safety profile and no new safety signals.
Regulatory Actions: The FDA granted expanded access to daraxonrasib for patients with previously treated metastatic PDAC. Revolution intends to submit an NDA under the CNPV program and to submit data to other global regulatory authorities.
Executive Impact: The NEJM simultaneous publication is the gold standard for pivotal oncology data. The PFS data (HR 0.49 in ITT, HR 0.45 in RAS G12) were the missing piece from the April topline readout and confirm that daraxonrasib delays disease progression by the same magnitude as it extends survival. The consistency between RAS G12 and ITT populations means patients without identified RAS mutations also benefit, supporting a broad label. With expanded access granted, CNPV filing imminent, and Truist projecting Q3 approval, daraxonrasib is on the fastest path from Phase 3 to market of any oncology drug in recent memory.
🔬 ASCO Plenary: The Other Two Practice-Changing Datasets
Ivonescimab Makes History as First Chinese Drug in ASCO Plenary Summit Therapeutics (SMMT) | Akeso (9926.HK)
Akeso presented overall survival data from the Phase 3 HARMONi-6 trial showing ivonescimab (PD-1/VEGF bispecific antibody) plus chemotherapy achieved a statistically significant and clinically meaningful OS improvement over tislelizumab (PD-1) plus chemotherapy in first-line advanced squamous NSCLC (HR 0.66). Professor Shun Lu (Shanghai Chest Hospital) presented the data. Akeso CEO Dr. Yu Xia said ivonescimab has "successfully challenged PD-1 plus chemotherapy, achieving both clinically meaningful and statistically significant improvements in overall survival and progression-free survival." This is the first time a China-originated investigational oncology drug has been selected for the ASCO plenary in the society's 61-year history. Summit Therapeutics holds U.S. rights.
J&J's Erleada Shifts a 125-Year Prostate Cancer Paradigm JNJ
Johnson & Johnson presented Phase 3 PROTEUS results showing Erleada (apalutamide) given before and after surgery significantly reduced the risk of metastasis or death versus hormone therapy alone in patients with high-risk localized or locally advanced prostate cancer. The 2,000-patient study opened the plenary session. J&J's U.S. president of oncology for solid tumors, Biljana Naumovic, told Fierce Pharma that the prostatectomy treatment paradigm has been essentially unchanged "since the prostatectomy was introduced 125 years ago in 1904." J&J oncology VP Mark Wildgust described the perioperative setting as "one chance for curing this patient."
📊 ASCO 2026 Plenary Scorecard
Presentation | Result | Impact |
|---|---|---|
Revolution RASolute 302 (pancreatic cancer) | OS HR 0.40, PFS HR 0.49, NEJM published | Practice-changing. CNPV filing imminent. Expanded access granted. |
Akeso ivonescimab HARMONi-6 (squamous NSCLC) | OS HR 0.66 vs PD-1 + chemo | First China drug in ASCO plenary. Potential Keytruda challenger. |
J&J Erleada PROTEUS (prostate cancer) | Reduced metastasis/death risk vs hormone therapy | 125-year paradigm shift. Perioperative label expansion expected. |
📅 The Week Ahead
Today/Tomorrow: ASCO 2026 continues (closes June 2)
June 4: Jefferies Global Healthcare Conference (New York)
June 2026: Takeda CEO transition (Julie Kim)
Late Q2: Lilly Foundayo T2D filing under CNPV
Q3 2026: Revolution Medicines daraxonrasib approval projected (Truist)
July 1: Medicare GLP-1 Bridge program launches
🔓 BioMed Nexus Pro: Institutional Intelligence Brief
🧠 RASolute 302: The Complete Picture
The full dataset answers every question the topline left open:
PFS confirmed: HR 0.49 in ITT, HR 0.45 in RAS G12. Daraxonrasib doubled PFS (7.2 vs. 3.6 months). This is the data point that was missing from the April readout and is critical for FDA labeling.
Broad efficacy confirmed: ITT results (which include patients without identified RAS mutations) were consistent with RAS G12 results. This supports a broad label rather than a biomarker-restricted indication.
NEJM publication: The simultaneous NEJM publication elevates the data from a conference presentation to a peer-reviewed benchmark. This is rare for ASCO presentations and signals the editors viewed the data as practice-changing.
Expanded access: The FDA granted expanded access before formal approval, meaning patients can start receiving daraxonrasib now. This is the strongest possible regulatory signal short of approval itself.
What comes next: CNPV NDA filing (expected within weeks). If CNPV mirrors Foundayo (50 days), approval August or September 2026. Revolution has $4B in cash. Commercialization infrastructure is being built. Peak sales estimates range from $2B to $4B for pancreatic cancer alone, with NSCLC expansion potentially doubling the opportunity.
💊 Ivonescimab: The U.S. Path
The HARMONi-6 OS data (HR 0.66) are impressive. But the path from ASCO plenary to U.S. FDA approval is complicated:
Chinese-only trial: HARMONi-6 enrolled exclusively Chinese patients. The FDA will scrutinize whether results are generalizable to a U.S./global population.
Comparator: The control arm was tislelizumab (BeOne Medicines), a PD-1 inhibitor not widely used in the U.S. The FDA and U.S. oncologists will want to see ivonescimab versus Keytruda, the U.S. standard of care.
Summit Therapeutics: The U.S. partner is a small company. Commercializing against Merck's Keytruda franchise requires deep commercial infrastructure that Summit currently lacks.
HARMONi-02: A separate Akeso study previously showed ivonescimab beat Keytruda in PFS in a different NSCLC population. OS data from HARMONi-02 (if positive) would strengthen the U.S. case.
The bull case: the dual PD-1/VEGF mechanism genuinely outperforms single-agent PD-1 inhibition, and the data are strong enough for an accelerated FDA pathway. The bear case: the FDA requires a U.S. confirmatory trial, which adds years to the timeline.
📊 PROTEUS: What Changes in Prostate Cancer
The PROTEUS result addresses a treatment gap that has existed since 1904. Currently, patients with high-risk localized prostate cancer receive surgery (prostatectomy) plus hormone therapy (ADT). No additional systemic therapy is standard of care in this setting.
PROTEUS showed that adding Erleada (apalutamide) before and after surgery significantly reduced the risk of metastasis or death. In a 2,000-patient study, this is a robust result. If approved, it would be the first systemic treatment change in perioperative prostate cancer in over a century.
The commercial implication: Erleada is already a multi-billion dollar franchise for J&J in advanced prostate cancer. Adding a perioperative indication expands the addressable population to the large number of radical prostatectomies performed annually in the U.S., representing meaningful incremental revenue.
🎯 Catalyst Calendar: June 2026 Forward
Date | Event | Tickers |
|---|---|---|
Today/Tomorrow | ASCO 2026 continues (closes June 2) | Multiple |
June 4 | Jefferies Global Healthcare Conference (New York) | Multiple |
June 2026 | Takeda CEO transition (Julie Kim) | TAK |
Imminent | Revolution Medicines CNPV NDA filing expected | RVMD |
Late Q2 | Lilly Foundayo T2D filing under CNPV | LLY |
Q3 2026 | Revolution Medicines daraxonrasib approval projected (Truist) | RVMD |
July 1 | Medicare GLP-1 Bridge program launches | LLY, NVO |
Q3 2026 | Teva/Emalex close expected | TEVA |
July 31 | Section 232 pharma tariffs effective (large companies) | Multiple |
H2 2026 | Merck sac-TMT global filing expected | MRK |
H2 2026 | Foundayo T2D regulatory action expected | LLY |
H2 2026 | Lilly/Kelonia close expected | LLY |
H2 2026 | Ajax proof-of-concept data expected | LLY |
2026 | TRIUMPH-2 (retatrutide T2D) readout expected | LLY |
Late 2026/Early 2027 | BridgeBio BBP-418 PDUFA (Priority Review) | BBIO |
Dec 2026 | Mineralys lorundrostat PDUFA | MLYS |
2027 | Retatrutide launch anticipated (BMO) | LLY |
Dec 7 | Lilly Investment Community Meeting | LLY |
Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →
Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →